Skip to content

Released May 20, 2026, before the open

10-K filed May 20, 2026, 50 days after period end · 0001764013-26-000064

Q4 2026 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$147.86MderivedN/M vs Q4 2025N/M vs Q3 2026
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived-$95,059,000N/M
Free Cash Flowderived-$95,067,000N/M

What the release said

The release

Same quarter

MetricQ4 2026derived from reported figuresQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figures
Net Income-$147.86M-$106.45M-$75.32M-$59.43M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR